Mental disorders associated with the novel coronavirus infection coronavirus disease-2019

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


This study presents data from recent publications on the occurrence of mental disorders during the coronavirus disease-2019 (COVID-19) pandemic and the specifics of providing mental health care under social isolation conditions. The issues of negative psychopathological outcome prevention in persons with high-risk mental disorders are considered, as well as the problems of organizing psychiatric care provision during the pandemic, including the possibility of remote counseling and follow-up. The questions of the pathogenesis of psychopathological symptoms in coronavirus infection are discussed. Particular attention is paid to the adverse effects of COVID-19 therapy, psychotropic drugs interactions, and drug treatment for patients with coronavirus infection. The research results and opinions of Russian and international specialists in the field of mental health that are presented in this review are relevant for medical practitioners working in the pandemic.

Full Text

Restricted Access

About the authors

Leonid M. Bardenshteyn

A.I. Evdokimov Moscow State University of Medicine and Dentistry

ORCID iD: 0000-0002-1171-5517

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Galina A. Aleshkina

A.I. Evdokimov Moscow State University of Medicine and Dentistry

ORCID iD: 0000-0002-8872-9810

MD, Dr. Sci. (Med.), assistant professor, Professor

Russian Federation, Moscow

Margarita E. Pugacheva

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
ORCID iD: 0000-0001-5956-5768

аssistant lecturer

Russian Federation, Moscow

Irina I. Kruglikova

A.I. Evdokimov Moscow State University of Medicine and Dentistry

ORCID iD: 0000-0002-9404-3452
Russian Federation, Moscow


  1. Kelly BD. Coronavirus disease: challenges for psychiatry. Br J Psychiatry. 2020;217(1):352–353. doi: 10.1192/bjp.2020.86
  2. Li Z, Ge J, Yang M, et al. Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain Behav Immun. 2020;88:916–919. doi: 10.1016/j.bbi.2020.03.007
  3. Sorokin MY, Kas'yanov ED, Rukavishnikov GV, et al. Struktura trevozhnykh perezhivanii, assotsiirovannykh s rasprostraneniem COVID-19: dannye onlain-oprosa. Vestnik RGMU. 2020;(3):74–84. (In Russ). doi: 10.24075/vrgmu.2020.030
  4. Goularte JF, Serafim SD, Colombo R, et al. COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. J Psychiatr Res. 2021;132:32–37. doi: 10.1016/j.jpsychires.2020.09.021
  5. Mosolov SN. Aktual'nye zadachi psikhiatricheskoi sluzhby v svyazi s pandemiei COVID-19. Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;(2):26–32. (In Russ). doi: 10.21265/PSYPH.2020.53.59536
  6. Roy D, Tripathy S, Kar SK, et al. Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic. Asian J Psychiatr. 2020;51:102083. doi: 10.1016/j.ajp.2020.102083
  7. Qiu J, Shen B, Zhao M, et al. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatr. 2020;33(2):e100213. doi: 10.1136/gpsych-2020-100213
  8. Abba-Aji A, Li D, Hrabok M, et al. COVID-19 Pandemic and Mental Health: Prevalence and Correlates of New-Onset Obsessive-Compulsive Symptoms in a Canadian Province. Int J Environ Res Public Health. 2020;17(19). doi: 10.3390/ijerph17196986
  9. Karatzias T, Shevlin M, Murphy J, et al. Posttraumatic Stress Symptoms and Associated Comorbidity During the COVID-19 Pandemic in Ireland: A Population-Based Study. J Trauma Stress. 2020;33(4):365–370. doi: 10.1002/jts.22565
  10. Sallie SN, Ritou V, Bowden-Jones H, Voon V. Assessing international alcohol consumption patterns during isolation from the COVID-19 pandemic using an online survey: highlighting negative emotionality mechanisms. BMJ Open. 2020;10(11):e044276. doi: 10.1136/bmjopen-2020-044276
  11. Shi L, Lu ZA, Que JY, et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3(7):e2014053. doi: 10.1001/jamanetworkopen.2020.14053
  12. Haider, II, Tiwana F, Tahir SM. Impact of the COVID-19 Pandemic on Adult Mental Health. Pak J Med Sci. 2020;36(COVID19-S4):S90–S94. doi: 10.12669/pjms.36.COVID19-S4.2756
  13. Kaufman KR, Petkova E, Bhui KS, Schulze TG. A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic. BJPsych Open. 2020;6(3):e48. doi: 10.1192/bjo.2020.25
  14. Vasileva AV. Pandemic and mental adjustment disorders. Therapy options. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(5):146–152. (In Russ). doi: 10.17116/jnevro2020120051146
  15. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54(9):906–914. doi: 10.1016/s0006-3223(03)00173-2
  16. Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–215. doi: 10.1016/j.bbi.2015.06.001
  17. Arteaga-Henriquez G, Simon MS, Burger B, et al. Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Front Psychiatry. 2019;10:458. doi: 10.3389/fpsyt.2019.00458
  18. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2(11):1002–1012. doi: 10.1016/S2215-0366(15)00309-0
  19. Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437(1):57–67. doi: 10.1111/nyas.13712
  20. Debnath M., Berk M., Maes M. Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic. Brain, behavior, & immunity-health. 2020; 5. doi: 100096. 10.1016/j.bbih.2020.100096
  21. Pisova NV, Pisov AV. Depressiya i posttravmaticheskoe stressovoe rasstroistvo pri novoi koronavirusnoi infektsii. Lechebnoe delo. 2020;(1):82–88.(In Russ). doi: 10.24411/2071-5315-2020-12197
  22. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. doi: 10.1016/S2215-0366(20)30203-0
  23. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi: 10.1038/nri.2015.5
  24. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912–920. doi: 10.1016/S0140-6736(20)30460-8
  25. Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600. doi: 10.1016/j.bbi.2020.07.037
  26. Benedetti F, Mazza M, Cavalli G, et al. Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021;16(1):1–3. doi: 10.1007/s11481-020-09966-z
  27. Bilbul M, Paparone P, Kim AM, et al. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411–427. doi: 10.1016/j.psym.2020.05.006
  28. Garcia P, Revet A, Yrondi A, et al. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A Vigi Base Study. Drug Saf. 2020;43(12):1315–1322. doi: 10.1007/s40264-020-01013-3
  29. Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Res. 2020;9:636. doi: 10.12688/f1000research.24457.1
  30. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;277:55–64. doi: 10.1016/j.jad.2020.08.001
  31. Sakib N, Akter T, Zohra F, et al. Fear of COVID-19 and Depression: A Comparative Study Among the General Population and Healthcare Professionals During COVID-19 Pandemic Crisis in Bangladesh. Int J Ment Health Addict. 2021:1–17. doi: 10.1007/s11469-020-00477-9
  32. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020;89:531–542. doi: 10.1016/j.bbi.2020.05.048
  33. Ustun G. Determining depression and related factors in a society affected by COVID-19 pandemic. Int J Soc Psychiatry. 2021;67(1):54–63. doi: 10.1177/0020764020938807
  34. Bonsaksen T, Heir T, Schou-Bredal I, et al. Post-Traumatic Stress Disorder and Associated Factors during the Early Stage of the COVID-19 Pandemic in Norway. Int J Environ Res Public Health. 2020;17(24). doi: 10.3390/ijerph17249210
  35. Almeida M, Shrestha AD, Stojanac D, Miller LJ. The impact of the COVID-19 pandemic on women's mental health. Arch Womens Ment Health. 2020;23(6):741–748. doi: 10.1007/s00737-020-01092-2
  36. Javed B, Sarwer A, Soto EB, Mashwani ZU. The coronavirus (COVID-19) pandemic's impact on mental health. Int J Health Plann Manage. 2020;35(5):993–996. doi: 10.1002/hpm.3008
  37. Dubey S, Biswas P, Ghosh R, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14(5):779–788. doi: 10.1016/j.dsx.2020.05.035
  38. Banerjee D. 'Age and ageism in COVID-19': Elderly mental health-care vulnerabilities and needs. Asian J Psychiatr. 2020;51:102154. doi: 10.1016/j.ajp.2020.102154
  39. Kholmogorova AB, Petrikov SS, Suroyegina AY, et al. Burnout and its Factors in Healthcare Workers Involved in Providing Health Care for Patients With COVID-19 at Different Stages of the Pandemic. Russian Sklifosovsky Journal "Emergency Medical Care". 2020;9(3):321–337. (In Russ). doi: 10.23934/2223-9022-2020-9-3-321-337
  40. Mosolov SN. Problems of mental health in the situation of COVID-19 pandemic. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2020;120(5):7. (In Russ). doi: 10.17116/jnevro20201200517
  41. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–106. doi: 10.1016/j.bbi.2020.04.069
  42. Navarro C, Yanez AM, Garcia A, et al. Effectiveness of a healthy lifestyle promotion program as adjunctive teletherapy for treatment-resistant major depression during COVID-19 pandemic: A randomized clinical trial protocol. Medicine (Baltimore). 2020;99(45):e22958. doi: 10.1097/MD.0000000000022958
  43. Luykx JJ, van Veen SMP, Risselada A, et al. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020;217(3):471–474. doi: 10.1192/bjp.2020.92
  44. Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry. 2020;217(1):351. doi: 10.1192/bjp.2020.84
  45. Chatterjee SS, Malathesh BC, Das S, Singh OP. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Asian J Psychiatr. 2020;52:102173. doi: 10.1016/j.ajp.2020.102173
  46. Dotson S, Hartvigsen N, Wesner T, et al. Clozapine Toxicity in the Setting of COVID-19. Psychosomatics. 2020;61(5):577–578.
  47. doi: 10.1016/j.psym.2020.05.025
  48. Mosolov SN, Malin DI, Tsukarzi EE, Kostyukova EG. Drug therapy for patients with mental disorders who have a coronavirus infection (COVID-19). Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;(2):34–38. (In Russ). doi: 10.21265/PSYPH.2020.18.69.001
  49. Hamed MGM, Hagag RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Med Hypotheses. 2020;144:110140. doi: 10.1016/j.mehy.2020.110140
  50. Drobizhev MY. COVID-19 and Selective Serotonin Reuptake Inhibitors. Clinical Protective Effects of Fluvoxamine in Patients with COVID-19. Nervnye bolezni. 2020;(3):52–56. (In Russ). doi: 10.24411/2226-0757-2020-12230
  51. Ma K, Wang X, Feng S, et al. From the perspective of Traditional Chinese Medicine: Treatment of mental disorders in COVID-19 survivors. Biomed Pharmacother. 2020;132:110810. doi: 10.1016/j.biopha.2020.110810

Copyright (c) 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies